<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type="iso-abbrev">Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type="publisher-id">DEE</journal-id><journal-title-group><journal-title>Dementia and Geriatric Cognitive Disorders EXTRA</journal-title></journal-title-group><issn pub-type="ppub">1664-5464</issn><issn pub-type="epub">1664-5464</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box &#x000b7; Postfach &#x000b7; Case postale, CH&#x02013;4009, Basel, Switzerland &#x000b7; Schweiz &#x000b7; Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3808222</article-id><article-id pub-id-type="doi">10.1159/000354369</article-id><article-id pub-id-type="publisher-id">dee-0003-0272</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Genetic Association between Neurotrophin-3 Polymorphisms and Alzheimer's Disease in Japanese Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nagata</surname><given-names>Tomoyuki</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Shibata</surname><given-names>Nobuto</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shinagawa</surname><given-names>Shunichiro</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nakayama</surname><given-names>Ritsuko</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kuerban</surname><given-names>Bolati</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ohnuma</surname><given-names>Tohru</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Arai</surname><given-names>Heii</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nakayama</surname><given-names>Kazuhiko</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yamada</surname><given-names>Hisashi</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib></contrib-group><aff id="aff1"><sup>a</sup>Department of Psychiatry, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan</aff><aff id="aff2"><sup>b</sup>Division of Molecular Genetics, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan</aff><aff id="aff3"><sup>c</sup>Department of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan</aff><author-notes><corresp id="cor1">*Tomoyuki Nagata, Division of Molecular Genetics, Institute of DNA Medicine, Jikei University School of Medicine, 3-25-8 Nishishimbashi, Minato-ku, Tokyo 105-8471 (Japan), E-Mail <email>t.nagata@jikei.ac.jp</email></corresp></author-notes><pub-date pub-type="collection"><season>Jan-Dec</season><year>2013</year></pub-date><pub-date pub-type="epub"><day>7</day><month>9</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>9</month><year>2013</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the							<pub-date pub-type="epub"/>. --><volume>3</volume><issue>1</issue><fpage>272</fpage><lpage>280</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 by S. Karger AG, Basel</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.</license-p></license></permissions><abstract><sec><title>Background</title><p>Some polymorphisms of the neurotrophin family have previously been investigated as candidate genes for Alzheimer's disease (AD). In the present study, we examined whether neurotrophin-3 (NTF-3) polymorphisms are genetic risk factors in patients with AD.</p></sec><sec><title>Methods</title><p>From a sample of 507 subjects, we recruited 248 age-matched subjects divided into 2 groups: AD patients (n = 143) and normal controls (NCs) (n = 105). We identified 3 representative <italic>NTF-3</italic> single nucleotide polymorphisms (SNPs): rs6332, rs6489630, and rs4930767. Next, we statistically compared the allele frequencies of each SNP between the AD and NC groups in the early-onset (&#x0003c;65 years) cases under a more limited age-matched condition.</p></sec><sec><title>Results</title><p>We found a significant association between rs6332 and the total group of AD patients (p = 0.013) and significant associations between both rs6332 (p = 0.033) and rs6489630 (p = 0.035) and early-onset AD patients.</p></sec><sec><title>Conclusion</title><p>These results suggest that <italic>NTF-3</italic> SNPs may not only be associated with AD itself, but also with early-onset AD in Japanese patients, assuming that the <italic>NTF-3</italic> gene may have age-related effects on neurodegenerative diseases.</p></sec></abstract><kwd-group><title>Key Words&#x02029;</title><kwd>Neurotrophin-3</kwd><kwd>Single nucleotide polymorphisms</kwd><kwd>Alzheimer's disease</kwd><kwd>Neurotrophins</kwd><kwd>Polymorphism&#x02029;</kwd></kwd-group><counts><table-count count="4"/><ref-count count="34"/><page-count count="9"/></counts></article-meta></front><body><sec id="sec1_1"><title>Introduction</title><p>Alzheimer's disease (AD) has a progressive neurodegenerative course characterized mainly by memory disorder, visuospatial impairment, and executive dysfunction as its core symptoms [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. The deposition of causative proteins, such as amyloid-beta (A&#x003b2;) and tau, in the pathogenesis of AD has previously been reported and has been focused on as a possible therapeutic target [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. <italic>APOE</italic> has been considered as a strong candidate gene for sporadic AD since the 1990s, and this speculation has recently been verified in a large-sample genome-wide association study [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. In Japan, a significant association between <italic>APOE</italic> and late-onset AD was replicated in a recent large-scale study [<xref ref-type="bibr" rid="B8">8</xref>]. On the other hand, various lifestyle-related diseases have been reported as risk factors, and sporadic AD itself is considered to be caused by a combination of several genetic and environmental factors [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>].</p><p>In postmortem analyses of the brain of patients with AD, regional quantitative alterations in neurotrophins, such as nerve growth factor, brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NTF-3), have been reported [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Similar results were obtained in AD mouse models, and these neurotrophins have been considered as practical therapeutic targets in AD patients or rodents [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. Among such representative neurotrophins, NTF-3, in particular, protects cortical neurons against A&#x003b2;-dependent neural cell death by limiting caspase-8, caspase-9, and caspase-3 cleavage [<xref ref-type="bibr" rid="B17">17</xref>]. On the other hand, NTF-3 influences the development of mesolimbic dopaminergic neurons and the differentiation of noradrenergic neurons in the locus ceruleus [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>].</p><p>While some previous studies had reported BDNF polymorphisms to be risk factors for AD in Japanese populations, we observed that some single nucleotide polymorphisms (SNPs) of neurotrophins are associated with cognitive impairment in patients with AD [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Among the candidate genes in the neurotrophin family, Kunugi et al. [<xref ref-type="bibr" rid="B23">23</xref>] found that a missense mutation (Gly/-63/Glu) in the <italic>NTF-3</italic> gene was associated with a risk of AD; however, its mutant type (-63 Glu) was too rare in Caucasian populations to be investigated in subsequent studies in other countries [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. On the other hand, <italic>NTF-3</italic> has been reported to be a strong candidate gene for attention deficit/hyperactivity disorder (ADHD), in which social cognition is impaired as a core symptom in the neurodevelopmental course [<xref ref-type="bibr" rid="B27">27</xref>]. <italic>NTF-3</italic> SNPs (rs6332 and rs6489630) are functional polymorphisms located at chromosome 12p13 and are significantly associated with the severity of ADHD and intelligence (i.e. selective attentional tasks and performance execution) [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. A silent polymorphism, rs6332, is located within Pro-<italic>NTF-3</italic> gene exon 1 and influences the executive function in patients with limited mild-stage AD, but not mild cognitive impairment (MCI) [<xref ref-type="bibr" rid="B20">20</xref>]. The rs4930767 polymorphism in the promoter region of the same gene does not appear to be associated with any measure of ADHD [<xref ref-type="bibr" rid="B29">29</xref>]. Based on these studies, the neurodevelopmental or neurodegenerative associated gene, <italic>NTF-3,</italic> may influence the age-related effects during the course of the disease, and such confounding effects should be considered when comparing the disease group and the normal control (NC) group.</p><p>In the present study, we hypothesized that representative <italic>NTF-3</italic> SNPs (rs6332, rs6489630, and rs4930767) might be associated with a risk of AD in Japanese subjects, a topic that is of particular interest in view of Japan's aging society. Thus, to investigate the association between AD and <italic>NTF-3</italic> SNPs without age as a confounding factor, we statistically compared the allele frequencies of 3 SNPs between AD patients and age-matched NCs. Moreover, to compare these 2 groups under stricter or more limited age-matched conditions, we selected only the early-onset sample (&#x0003c;65 years) from the total sample (age range, 32-72 years) in the second stage of the analysis [<xref ref-type="bibr" rid="B9">9</xref>].</p></sec><sec sec-type="methods" id="sec1_2"><title>Methods</title><sec id="sec2_1"><title>Participants</title><p>Of the 507 Japanese subjects enrolled in the present genomic study, including patients with AD (n = 340; age range, 35-92 years; mean &#x000b1; SD, 72.41 &#x000b1; 10.71 years), patients with MCI (n = 47; age range, 63-83 years; mean &#x000b1; SD, 75.26 &#x000b1; 4.56 years), and NCs (n = 120; age range, 32-81 years; mean &#x000b1; SD, 61.86 &#x000b1; 8.41 years), we excluded 47 patients with MCI and 212 subjects (AD: n = 197; NCs: n = 15) who were older than 73 years. Thus, an age-matched sample (age range, 32-72 years; mean &#x000b1; SD, 61.20 &#x000b1; 7.24 years) of 248 subjects (AD: n = 143; NCs: n = 105) was recruited. All subjects were outpatients who had visited a memory clinic at the Jikei University Hospital (Tokyo), the Jikei University Kashiwa Hospital (Kashiwa city, Chiba prefecture), or the Juntendo University Hospital (Tokyo). They were all diagnosed with probable AD based on the National Institute of Neurology and Communicative Disorder and Stroke/Alzheimer Disease and Related Disorder Association (NINCDS/ADRDA) criteria or the diagnostic criteria for MCI [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. This study was approved by the Ethics Committee of the Jikei University School of Medicine (Tokyo and Kashiwa) and Juntendo University School of Medicine (Tokyo). Written informed consent was obtained from both the patients and their caregivers.</p></sec><sec id="sec2_2"><title>Identification of NTF-3 SNP Genotypes</title><p>The method used to identify the <italic>NTF-3</italic> SNP (rs6332, rs6489630, rs4930767) genotypes, a SNaPshot analysis (Applied Biosystems, Foster City, Calif., USA), has been described in previous reports [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. If the genotype of the SNP was unclear or ambiguous when determined using the SNaPshot method, we rechecked and confirmed the genotype using PCR products and direct nucleotide sequencing using an ABI 3730 DNA Analyzer [sequencing reactions were performed using BigDye Terminator v3.1 Cycle Sequencing Kits (Applied Biosystems)]. All sequence analyses were performed using DNA Sequencing Analysis software, version 5.3.1 (Applied Biosystems).</p></sec><sec id="sec2_3"><title>Comparing Allele Frequencies of rs6332, rs6489630, and rs4930767 between the Total and Early-Onset Group of Patients and the NCs</title><p>We statistically compared the allele frequencies of the <italic>NTF-3</italic> SNPs (rs6332, rs6489630, rs4930767) between all patients with AD (total) and the NCs. Next, to investigate the relation under a more limited age-matched condition, we analyzed 163 (AD: n = 86; NCs: n = 77) early-onset cases (&#x0003c;65 years); the frequencies of each allele were the same between the AD patients and the NCs.</p></sec><sec id="sec2_4"><title>Statistical Analysis</title><p>SPSS 19.0J for Windows (SPSS Japan Inc.) was used for all statistical analyses. To control for type I errors, we used a one-way ANOVA with a post hoc Tukey test for age. The sex ratio (female to male) and allele frequencies of the <italic>NTF-3</italic> SNPs were assessed using the Fisher exact probability test; the odds ratio (OR) was then calculated. A &#x003c7;<sup>2</sup> test was used to compare the distributions among the 3 genotypic groups. To assess the deviation of SNPs from Hardy-Weinberg equilibrium (HWE), we used the HWE calculator Web program (<ext-link ext-link-type="uri" xlink:href="http://www.oege.org/software/hwe-mr-calc.shtml">http://www.oege.org/software/hwe-mr-calc.shtml</ext-link>). Moreover, we performed power calculations using the G* Power 3 (<ext-link ext-link-type="uri" xlink:href="http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/">http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/</ext-link>). A p value &#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec1_3"><title>Results</title><sec id="sec2_5"><title>Characteristics, Genotype Distributions, and Allele Frequencies of All Subjects</title><p>Among the 248 subjects that were selected, the age and sex ratios of the patients with AD (n = 143) were not significantly different from those of the NCs (n = 105) (tables <xref ref-type="table" rid="T1">1</xref>, <xref ref-type="table" rid="T2">2</xref>). The genotype distributions of rs6332 (G/G: n = 71, G/A: n = 130, A/A: n = 45), rs6489630 (C/C: n = 141, C/T: n = 93, T/T: n = 11), and rs4930767 (T/T: n = 94, C/T: n = 112, C/C: n = 40) among the total patient group did not deviate significantly from the HWE (p &#x0003e; 0.05) (tables <xref ref-type="table" rid="T3">3</xref>, <xref ref-type="table" rid="T4">4</xref>). The results of power analyses demonstrated that the power ranged from 50.8% (rs6332) to 78.9% (rs4930767). The genotypic distribution of rs6332 was significantly deviated (&#x003c7;<sup>2</sup> = 6.979, d.f. <italic>=</italic> 2, p = 0.031) and its allele frequency was significantly different between the patients with AD and the NCs (&#x003c7;<sup>2</sup> = 6.496, d.f. = 1, p = 0.013, OR = 1.602) (tables <xref ref-type="table" rid="T3">3</xref>, <xref ref-type="table" rid="T4">4</xref>). However, we could not find any significant differences in the genotypic allele frequencies of rs6489630 (&#x003c7;<sup>2</sup> = 3.523, d.f. = 1, p = 0.067, OR = 0.670) or rs4930767 (&#x003c7;<sup>2</sup> = 0.133, d.f. = 1, p = 0.779, OR = 1.071) between the patients with AD and the NCs (tables <xref ref-type="table" rid="T3">3</xref>, <xref ref-type="table" rid="T4">4</xref>).</p></sec><sec id="sec2_6"><title>Genotypic Distributions and Allele Frequencies in Subjects with an Age of Onset of Less than 65 Years</title><p>Next, 163 cases with early-onset AD (EAD: n = 86) and age-matched NCs (n = 77) were compared; the age and sex ratios were not significantly different between the EAD and NC groups (table <xref ref-type="table" rid="T3">3</xref>). The genotype distributions of rs6332 (G/G: n = 51, G/A: n = 84, A/A: n = 27), rs6489630 (C/C: n = 94, C/T: n = 59, T/T: n = 8), and rs4930767 (T/T: n = 63, C/T: n = 74, C/C: n = 25) in the EAD group did not deviate significantly from the HWE (p &#x0003e; 0.05) (table <xref ref-type="table" rid="T4">4</xref>). The results of power analyses demonstrated that the power ranged from 51.3% (rs6332) to 76.3% (rs4930767). While the 3 genotypic distributions were not significantly deviated, significant differences in the allele frequencies of rs6332 and rs6489630 were observed between the EAD group and the age-matched NCs (former: &#x003c7;<sup>2</sup> = 4.687, d.f. = 1, p = 0.033, OR = 1.631; latter: &#x003c7;<sup>2</sup> = 4.605, d.f. = 1, p = 0.035, OR = 0.566) (table <xref ref-type="table" rid="T4">4</xref>).</p></sec></sec><sec sec-type="discussion" id="sec1_4"><title>Discussion</title><p>In the present study, we found significant differences in the allele frequencies of the <italic>NTF-3</italic> SNPs between patients with AD and the NCs and between the EAD group (&#x0003c;65 years) and age-matched NCs (tables <xref ref-type="table" rid="T2">2</xref>, <xref ref-type="table" rid="T4">4</xref>). While the A allele of rs6332 was associated with a risk of AD and EAD (former: OR = 1.602, 95% CI = 1.114-2.304; latter: OR = 1.631, 95% CI = 1.045-2.545), the T allele of rs6489630 was associated with a protective role only for EAD (OR = 0.566, 95% CI = 0.335-0.955). We could not find a significant association between rs4930767 and the manifestation of AD (tables <xref ref-type="table" rid="T1">1</xref>, <xref ref-type="table" rid="T2">2</xref>, <xref ref-type="table" rid="T3">3</xref>, <xref ref-type="table" rid="T4">4</xref>).</p><p>In previous studies, rs6332 was reported to be a robust candidate gene polymorphism for ADHD and to influence intelligence [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. We found that the executive function of G allele carriers was significantly lower than that of A allele carriers among AD patients. However, carrying the A allele was associated with a risk of EAD in the present study [<xref ref-type="bibr" rid="B20">20</xref>]. The functional roles of rs6332 might influence executive dysfunction in comparatively older AD patients (approx. 74-76 years old) [<xref ref-type="bibr" rid="B20">20</xref>]. On the other hand, rs6332 might be associated with the manifestation of AD in patients with EAD.</p><p>Similarly, rs6489630 was reportedly associated with the intelligence of subjects with ADHD, and the intelligence scores of T allele carriers were significantly lower than those of C allele carriers [<xref ref-type="bibr" rid="B28">28</xref>]. In contrast, the present results indicate a predominantly protective role associated with the T allele, compared with C allele carriers, with regard to the manifestation of EAD. Thus, functional SNPs of neurotrophins might have age-related reversible influences clinically between the young and the elderly, similar to the <italic>BDNF</italic> gene Val66Met polymorphism [<xref ref-type="bibr" rid="B33">33</xref>]. Further investigations of age-dependent associations between the manifestation of AD and the <italic>NTF-3</italic> gene are needed.</p><p>A reduction in NTF-3 levels has been observed in septal regions containing neurotrophin-dependent cholinergic projections in APP mouse models [<xref ref-type="bibr" rid="B14">14</xref>]. Furthermore, NTF-3 protects cortical neurons against A&#x003b2;-dependent neural cell death through the regulation of the phosphorylation pathway [<xref ref-type="bibr" rid="B17">17</xref>]. The rs6332 SNP is a silent variation, and such synonymous polymorphisms have been implicated in the regulation of mRNA splicing or the translation of proteins [<xref ref-type="bibr" rid="B34">34</xref>]. Therefore, rs6332 might influence synonymous polymorphisms that in turn might impact the regional translational level of NTF-3, leading to the regulation of cholinergic neuron projections. The rs6489630 SNP is located in an intron on the 3&#x02032;-side, but its functional roles (e.g. transcriptional regulation of the <italic>NTF-3</italic> gene) remain unclear and require further examination in the future.</p><p>The present study has some limitations. First, the sample size in this study was comparatively small. Therefore, the statistical values were also small, and some type II errors may have occurred, possibly resulting in the failure to detect a significant association between rs4930767 and the risk of AD. To match the age (age range, 32-72 years) between the AD patients and NCs, we selected only 248 of the 507 participants. Moreover, we could not compare the relation between late-onset AD patients (&#x0003e;65 years) and age-matched NCs because the sample size was too small (n = 85). Regarding the statistical values, a previous study investigating the association between AD and the <italic>NTF-3</italic> gene in the Japanese population reported the same p values (score range, 0.011-0.013) [<xref ref-type="bibr" rid="B23">23</xref>]. Secondly, we could not confirm whether the significant differences in the allele frequencies between the patients with AD and the NCs had been influenced by neuroprotective actions against degenerative progression or neurodevelopmental factors. Thirdly, other representative SNPs in the Japanese population, such as the missense mutation Gly/-63/Glu, were not examined; however, the mutant type (-63 Glu) is too rare in Caucasian populations to be investigated in subsequent studies in other countries [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. Therefore, a larger sampling should be added to the present study, and the data should be re-evaluated in the future.</p><p>In conclusion, despite some limitations, we found a significant association between AD and <italic>NTF-3</italic> as well as between EAD and <italic>NTF-3</italic>. These results may help to elucidate the neuroprotective or clinical age-related roles of not only the <italic>NTF-3</italic> gene, but also other neurotrophin gene polymorphisms in neurodegenerative diseases described in previous studies [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B33">33</xref>]. Furthermore, elucidating the detailed associations between <italic>NTF-3</italic> gene diversity and the manifestation of AD itself will be an important task in the future.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baudic</surname><given-names>S</given-names></name><name><surname>Barba</surname><given-names>GD</given-names></name><name><surname>Thibaudet</surname><given-names>MC</given-names></name><name><surname>Smagghe</surname><given-names>A</given-names></name><name><surname>Remy</surname><given-names>P</given-names></name><name><surname>Traykov</surname><given-names>L</given-names></name></person-group><article-title>Executive function deficit in early Alzheimer's disease and their relations with episodic memory</article-title><source>Arch Clin Neuropsychol</source><year>2006</year><volume>21</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">16125364</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>RJ</given-names></name><name><surname>Watson</surname><given-names>P</given-names></name><name><surname>Hodge</surname><given-names>JR</given-names></name></person-group><article-title>The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment</article-title><source>Neuropsychologia</source><year>2000</year><volume>38</volume><fpage>252</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">10678692</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Kurz</surname><given-names>A</given-names></name></person-group><article-title>Current concepts in mild cognitive impairment</article-title><source>Arch Neurol</source><year>2001</year><volume>58</volume><fpage>1985</fpage><lpage>1992</lpage><pub-id pub-id-type="pmid">11735772</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Allsop</surname><given-names>D</given-names></name></person-group><article-title>Amyloid deposition as the central event in the aetiology of Alzheimer's disease</article-title><source>Trends Pharmacol Sci</source><year>1991</year><volume>12</volume><fpage>383</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">1763432</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol</source><year>1991</year><volume>82</volume><fpage>239</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">1759558</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corder</surname><given-names>EH</given-names></name><name><surname>Saunders</surname><given-names>AM</given-names></name><name><surname>Strittmatter</surname><given-names>WJ</given-names></name><name><surname>Schmechel</surname><given-names>DE</given-names></name><name><surname>Gaskell</surname><given-names>PC</given-names></name><name><surname>Small</surname><given-names>GW</given-names></name><name><surname>Roses</surname><given-names>AD</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name></person-group><article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families</article-title><source>Science</source><year>1993</year><volume>261</volume><fpage>921</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">8346443</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harold</surname><given-names>D</given-names></name><name><surname>Abraham</surname><given-names>R</given-names></name><name><surname>Hollingworth</surname><given-names>P</given-names></name><name><surname>Sims</surname><given-names>R</given-names></name><name><surname>Gerrish</surname><given-names>A</given-names></name><name><surname>Hamshere</surname><given-names>ML</given-names></name><name><surname>Pahwa</surname><given-names>JS</given-names></name><name><surname>Moskvina</surname><given-names>V</given-names></name><etal/></person-group><article-title>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>1088</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">19734902</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohara</surname><given-names>T</given-names></name><name><surname>Ninomiya</surname><given-names>T</given-names></name><name><surname>Hirakawa</surname><given-names>Y</given-names></name><name><surname>Ashikawa</surname><given-names>K</given-names></name><name><surname>Monji</surname><given-names>A</given-names></name><name><surname>Kiyohara</surname><given-names>Y</given-names></name><name><surname>Kanba</surname><given-names>S</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name></person-group><article-title>Association study of susceptibility genes for late-onset Alzheimer's disease in the Japanese population</article-title><source>Psychiatr Genet</source><year>2012</year><volume>22</volume><fpage>290</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">22935915</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettens</surname><given-names>K</given-names></name><name><surname>Sleegers</surname><given-names>K</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name></person-group><article-title>Current status on Alzheimer disease molecular genetics: from past, to present, to future</article-title><source>Hum Mol Genet</source><year>2010</year><volume>19</volume><issue>R1</issue><fpage>R4</fpage><lpage>R11</lpage><pub-id pub-id-type="pmid">20388643</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohara</surname><given-names>T</given-names></name><name><surname>Doi</surname><given-names>Y</given-names></name><name><surname>Ninomiya</surname><given-names>T</given-names></name><name><surname>Hirakawa</surname><given-names>Y</given-names></name><name><surname>Hata</surname><given-names>J</given-names></name><name><surname>Iwaki</surname><given-names>T</given-names></name><name><surname>Kanba</surname><given-names>S</given-names></name><name><surname>Kiyohara</surname><given-names>Y</given-names></name></person-group><article-title>Glucose tolerance status and risk of dementia in the community: the Hisayama study</article-title><source>Neurology</source><year>2011</year><volume>77</volume><fpage>1126</fpage><lpage>1134</lpage><pub-id pub-id-type="pmid">21931106</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hock</surname><given-names>C</given-names></name><name><surname>Heese</surname><given-names>K</given-names></name><name><surname>Hulette</surname><given-names>C</given-names></name><name><surname>Rosenberg</surname><given-names>C</given-names></name><name><surname>Otten</surname><given-names>U</given-names></name></person-group><article-title>Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas</article-title><source>Arch Neurol</source><year>2000</year><volume>57</volume><fpage>846</fpage><lpage>851</lpage><pub-id pub-id-type="pmid">10867782</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durany</surname><given-names>N</given-names></name><name><surname>Michel</surname><given-names>T</given-names></name><name><surname>Kurt</surname><given-names>J</given-names></name><name><surname>Cruz-S&#x000e1;nchez</surname><given-names>FF</given-names></name><name><surname>Cerv&#x000f3;s-Navarro</surname><given-names>J</given-names></name><name><surname>Riederer</surname><given-names>P</given-names></name></person-group><article-title>Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains</article-title><source>Int J Dev Neurosci</source><year>2000</year><volume>18</volume><fpage>807</fpage><lpage>813</lpage></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narisawa-Saito</surname><given-names>M</given-names></name><name><surname>Wakabayashi</surname><given-names>K</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Nawa</surname><given-names>H</given-names></name></person-group><article-title>Regional specificity of alterations in NGF, BDNF and NTF-3 levels in Alzheimer's disease</article-title><source>Neuroreport</source><year>1996</year><volume>7</volume><fpage>2925</fpage><lpage>2928</lpage><pub-id pub-id-type="pmid">9116211</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulte-Herbr&#x000fc;ggen</surname><given-names>O</given-names></name><name><surname>Eckart</surname><given-names>S</given-names></name><name><surname>Deicke</surname><given-names>U</given-names></name><name><surname>K&#x000fc;hl</surname><given-names>A</given-names></name><name><surname>Otten</surname><given-names>U</given-names></name><name><surname>Danker-Hopfe</surname><given-names>H</given-names></name><name><surname>Abramowski</surname><given-names>D</given-names></name><name><surname>Staufenbiel</surname><given-names>M</given-names></name><name><surname>Hellweg</surname><given-names>R</given-names></name></person-group><article-title>Age-dependent time course of cerebral brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 in APP23 transgenic mice</article-title><source>J Neurosci Res</source><year>2008</year><volume>86</volume><fpage>2774</fpage><lpage>2783</lpage><pub-id pub-id-type="pmid">18438945</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagahara</surname><given-names>AH</given-names></name><name><surname>Merrill</surname><given-names>DA</given-names></name><name><surname>Coppola</surname><given-names>G</given-names></name><name><surname>Tsukada</surname><given-names>S</given-names></name><name><surname>Schroeder</surname><given-names>BE</given-names></name><name><surname>Shaked</surname><given-names>GM</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Blesch</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Conner</surname><given-names>JM</given-names></name><name><surname>Rockenstein</surname><given-names>E</given-names></name><name><surname>Chao</surname><given-names>MV</given-names></name><name><surname>Koo</surname><given-names>EH</given-names></name><name><surname>Geschwind</surname><given-names>D</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Chiba</surname><given-names>AA</given-names></name><name><surname>Tuszynski</surname><given-names>MH</given-names></name></person-group><article-title>Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease</article-title><source>Nat Med</source><year>2009</year><volume>15</volume><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">19198615</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuszynski</surname><given-names>MH</given-names></name><name><surname>Thal</surname><given-names>L</given-names></name><name><surname>Pay</surname><given-names>M</given-names></name><name><surname>Salmon</surname><given-names>DP</given-names></name><name><surname>U</surname><given-names>HS</given-names></name><name><surname>Bakay</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Blesch</surname><given-names>A</given-names></name><name><surname>Vahlsing</surname><given-names>HL</given-names></name><name><surname>Ho</surname><given-names>G</given-names></name><name><surname>Tong</surname><given-names>G</given-names></name><name><surname>Potkin</surname><given-names>SG</given-names></name><name><surname>Fallon</surname><given-names>J</given-names></name><name><surname>Hansen</surname><given-names>L</given-names></name><name><surname>Mufson</surname><given-names>EJ</given-names></name><name><surname>Kordower</surname><given-names>JH</given-names></name><name><surname>Gall</surname><given-names>C</given-names></name><name><surname>Conner</surname><given-names>J</given-names></name></person-group><article-title>A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease</article-title><source>Nat Med</source><year>2005</year><volume>11</volume><fpage>551</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">15852017</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesn&#x000e9;</surname><given-names>S</given-names></name><name><surname>Gabriel</surname><given-names>C</given-names></name><name><surname>Nelson</surname><given-names>DA</given-names></name><name><surname>White</surname><given-names>E</given-names></name><name><surname>Mackenzie</surname><given-names>ET</given-names></name><name><surname>Vivien</surname><given-names>D</given-names></name><name><surname>Buisson</surname><given-names>A</given-names></name></person-group><article-title>Akt-dependent expression of NAIP-1 protects neurons against amyloid-&#x003b2; toxicity</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>24941</fpage><lpage>24947</lpage><pub-id pub-id-type="pmid">15797869</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maness</surname><given-names>LM</given-names></name><name><surname>Kastin</surname><given-names>AJ</given-names></name><name><surname>Weber</surname><given-names>JT</given-names></name><name><surname>Banks</surname><given-names>WA</given-names></name><name><surname>Beckman</surname><given-names>BS</given-names></name><name><surname>Zadina</surname><given-names>JE</given-names></name></person-group><article-title>The neurotrophins and their receptors: structure, function, and neuropathology</article-title><source>Neurosci Biobehav Rev</source><year>1994</year><volume>18</volume><fpage>143</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">8170621</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maisonpierre</surname><given-names>PC</given-names></name><name><surname>Le Beau</surname><given-names>MM</given-names></name><name><surname>Espinosa</surname><given-names>R</given-names><suffix>3rd</suffix></name><name><surname>Ip</surname><given-names>NY</given-names></name><name><surname>Belluscio</surname><given-names>L</given-names></name><name><surname>de la Monte</surname><given-names>SM</given-names></name><name><surname>Squinto</surname><given-names>S</given-names></name><name><surname>Furth</surname><given-names>ME</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name></person-group><article-title>Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations</article-title><source>Genomics</source><year>1991</year><volume>10</volume><fpage>558</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">1889806</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>N</given-names></name><name><surname>Nagata</surname><given-names>T</given-names></name><name><surname>Shinagawa</surname><given-names>S</given-names></name><name><surname>Nakayama</surname><given-names>R</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name></person-group><article-title>Association between neurotrophin-3 polymorphisms and executive function in Japanese patients with amnestic mild cognitive impairment and mild Alzheimer disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2012</year><volume>34</volume><fpage>190</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">23075484</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>T</given-names></name><name><surname>Shinagawa</surname><given-names>S</given-names></name><name><surname>Nukariya</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name></person-group><article-title>Association between BDNF polymorphism (Val66Met) and executive function in patients with amnestic mild cognitive impairment or mild Alzheimer disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2012</year><volume>33</volume><fpage>266</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">22699449</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akatsu</surname><given-names>H</given-names></name><name><surname>Yamagata</surname><given-names>HD</given-names></name><name><surname>Kawamata</surname><given-names>J</given-names></name><name><surname>Kamino</surname><given-names>K</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Miki</surname><given-names>T</given-names></name><name><surname>Tooyama</surname><given-names>I</given-names></name><name><surname>Shimohama</surname><given-names>S</given-names></name><name><surname>Kosaka</surname><given-names>K</given-names></name></person-group><article-title>Variations in the BDNF gene in autopsy-confirmed Alzheimer's disease and dementia with Lewy bodies in Japan</article-title><source>Dement Geriatr Cogn Disord</source><year>2006</year><volume>22</volume><fpage>216</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">16899999</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunugi</surname><given-names>H</given-names></name><name><surname>Hattori</surname><given-names>M</given-names></name><name><surname>Ueki</surname><given-names>A</given-names></name><name><surname>Isse</surname><given-names>K</given-names></name><name><surname>Hirasawa</surname><given-names>H</given-names></name><name><surname>Nanko</surname><given-names>S</given-names></name></person-group><article-title>Possible association of missense mutation (Gly[-63]Glu) of the neurotrophin-3 gene with Alzheimer's disease in Japanese</article-title><source>Neurosci Lett</source><year>1998</year><volume>241</volume><fpage>65</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">9502217</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunugi</surname><given-names>H</given-names></name><name><surname>Ueki</surname><given-names>A</given-names></name><name><surname>Otsuka</surname><given-names>M</given-names></name><name><surname>Isse</surname><given-names>K</given-names></name><name><surname>Hirasawa</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>N</given-names></name><name><surname>Nabika</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Nanko</surname><given-names>S</given-names></name></person-group><article-title>A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease</article-title><source>Mol Psychiatry</source><year>2001</year><volume>6</volume><fpage>83</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">11244490</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>T</given-names></name><name><surname>Shinagawa</surname><given-names>S</given-names></name><name><surname>Nukariya</surname><given-names>K</given-names></name><name><surname>Nakayama</surname><given-names>R</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name></person-group><article-title>Association between nerve growth factor gene polymorphism and executive dysfunction in Japanese patients with early-stage Alzheimer's disease and amnestic mild cognitive impairment</article-title><source>Dement Geriatr Cogn Disord</source><year>2011</year><volume>32</volume><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">22301435</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x0014f;nsson</surname><given-names>E</given-names></name><name><surname>Bren&#x000e9;</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>XR</given-names></name><name><surname>Nimgaonkar</surname><given-names>VL</given-names></name><name><surname>Tylec</surname><given-names>A</given-names></name><name><surname>Schalling</surname><given-names>M</given-names></name><name><surname>Sedvall</surname><given-names>G</given-names></name></person-group><article-title>Schizophrenia and neurotrophin-3 alleles</article-title><source>Acta Psychiatr Scand</source><year>1997</year><volume>95</volume><fpage>414</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">9197906</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribas&#x000e9;s</surname><given-names>M</given-names></name><name><surname>Herv&#x000e1;s</surname><given-names>A</given-names></name><name><surname>Ramos-Quiroga</surname><given-names>JA</given-names></name><name><surname>Bosch</surname><given-names>R</given-names></name><name><surname>Bielsa</surname><given-names>A</given-names></name><name><surname>Gastaminza</surname><given-names>X</given-names></name><name><surname>Fern&#x000e1;ndez-Anguiano</surname><given-names>M</given-names></name><name><surname>Nogueira</surname><given-names>M</given-names></name><name><surname>G&#x000f3;mez-Barros</surname><given-names>N</given-names></name><name><surname>Valero</surname><given-names>S</given-names></name><name><surname>Gratac&#x000f2;s</surname><given-names>M</given-names></name><name><surname>Estivill</surname><given-names>X</given-names></name><name><surname>Casas</surname><given-names>M</given-names></name><name><surname>Cormand</surname><given-names>B</given-names></name><name><surname>Bay&#x000e9;s</surname><given-names>M</given-names></name></person-group><article-title>Association study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-deficit/hyperactivity disorder</article-title><source>Biol Psychiatry</source><year>2008</year><volume>63</volume><fpage>935</fpage><lpage>945</lpage><pub-id pub-id-type="pmid">18179783</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>SC</given-names></name><name><surname>Kim</surname><given-names>HW</given-names></name><name><surname>Kim</surname><given-names>BN</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Shin</surname><given-names>MS</given-names></name><name><surname>Cho</surname><given-names>DY</given-names></name><name><surname>Chung</surname><given-names>S</given-names></name><name><surname>Jung</surname><given-names>SW</given-names></name><name><surname>Yoo</surname><given-names>HJ</given-names></name><name><surname>Chung</surname><given-names>IW</given-names></name><name><surname>Chung</surname><given-names>US</given-names></name><name><surname>Son</surname><given-names>JW</given-names></name></person-group><article-title>Neurotrophin-3 gene, intelligence, and selective attention deficit in a Korean sample with attention-deficit/hyperactivity disorder</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2010</year><volume>34</volume><fpage>1065</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">20576502</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conner</surname><given-names>AC</given-names></name><name><surname>Kissling</surname><given-names>C</given-names></name><name><surname>Hodges</surname><given-names>E</given-names></name><name><surname>H&#x000fc;nnerkopf</surname><given-names>R</given-names></name><name><surname>Clement</surname><given-names>RM</given-names></name><name><surname>Dudley</surname><given-names>E</given-names></name><name><surname>Freitag</surname><given-names>CM</given-names></name><name><surname>R&#x000f6;sler</surname><given-names>M</given-names></name><name><surname>Retz</surname><given-names>W</given-names></name><name><surname>Thome</surname><given-names>J</given-names></name></person-group><article-title>Neurotrophic factor-related gene polymorphisms and adult attention deficit hyperactivity disorder (ADHD) score in a high-risk male population</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2008</year><volume>147B</volume><fpage>1476</fpage><lpage>1480</lpage><pub-id pub-id-type="pmid">18428117</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name></person-group><article-title>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">6610841</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Kurz</surname><given-names>A</given-names></name></person-group><article-title>Current concepts in mild cognitive impairment</article-title><source>Arch Neurol</source><year>2001</year><volume>58</volume><fpage>1985</fpage><lpage>1992</lpage><pub-id pub-id-type="pmid">11735772</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Cathcart</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Poduslo</surname><given-names>SE</given-names></name></person-group><article-title>Genetic variants in brain-derived neurotrophic factor associated with Alzheimer's disease</article-title><source>J Med Genet</source><year>2007</year><volume>44</volume><fpage>e66</fpage><pub-id pub-id-type="pmid">17293537</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voineskos</surname><given-names>AN</given-names></name><name><surname>Lerch</surname><given-names>JP</given-names></name><name><surname>Felsky</surname><given-names>D</given-names></name><name><surname>Shaikh</surname><given-names>S</given-names></name><name><surname>Rajji</surname><given-names>TK</given-names></name><name><surname>Miranda</surname><given-names>D</given-names></name><name><surname>Lobaugh</surname><given-names>NJ</given-names></name><name><surname>Mulsant</surname><given-names>BH</given-names></name><name><surname>Pollock</surname><given-names>BG</given-names></name><name><surname>Kennedy</surname><given-names>JL</given-names></name></person-group><article-title>The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease</article-title><source>Arch Gen Psychiatry</source><year>2011</year><volume>68</volume><fpage>198</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">21300947</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimchi-Sarfaty</surname><given-names>C</given-names></name><name><surname>Oh</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>IW</given-names></name><name><surname>Sauna</surname><given-names>ZE</given-names></name><name><surname>Calcagno</surname><given-names>AM</given-names></name><name><surname>Ambudkar</surname><given-names>SV</given-names></name><name><surname>Gottesman</surname><given-names>MM</given-names></name></person-group><article-title>A &#x02018;silent&#x02019; polymorphism in the MDR1 gene changes substrate specificity</article-title><source>Science</source><year>2007</year><volume>315</volume><fpage>525</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">17185560</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Total subject characteristics (n = 248)</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Total AD (n = 143)</th><th align="left" rowspan="1" colspan="1">NC (n = 105)</th><th align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> or F score</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">61.92 &#x000b1; 7.10</td><td align="left" rowspan="1" colspan="1">60.21 &#x000b1; 7.35</td><td align="left" rowspan="1" colspan="1">3.426</td><td align="left" rowspan="1" colspan="1">0.065</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex ratio (M/F)</td><td align="left" rowspan="1" colspan="1">67/76</td><td align="left" rowspan="1" colspan="1">44/61</td><td align="left" rowspan="1" colspan="1">0.600<xref ref-type="table-fn" rid="T1F1"><sup>a</sup></xref></td><td align="left" rowspan="1" colspan="1">0.518</td></tr></tbody></table><table-wrap-foot><fn><p>Values represent number of patients or means &#x000b1; SD.</p></fn><fn id="T1F1"><label>a</label><p>The &#x003c7;<sup>2</sup> score. One-way ANOVA with post hoc tests (Tukey) for age: AD versus NC.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Association between <italic>NTF-3</italic> and total AD patients</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">AD (n = 141)<xref ref-type="table-fn" rid="T2F2"><sup>1</sup></xref></th><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">NC (n = 105)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>rs6332</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Genotype frequency</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">G/G</td><td align="left" rowspan="1" colspan="1">33 (23.4%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">38 (36.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">76 (53.9%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">54 (51.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">A/A</td><td align="left" rowspan="1" colspan="1">32 (22.7%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">13 (12.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> score</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6.979</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.031<xref ref-type="table-fn" rid="T2F1"><sup>*</sup></xref></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Allele frequency</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">142 (50.4%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">130 (61.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">140 (49.6%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">80 (38.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> score</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6.496</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.013*</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">OR (95% CI)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.602 (1.114&#x02013;2.304)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>rs6489630</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Genotype frequency</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">C/C</td><td align="left" rowspan="1" colspan="1">87 (62.1%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">54 (51.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">49 (35.0%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">44 (41.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">T/T</td><td align="left" rowspan="1" colspan="1">4 (2.9%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7 (6.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> score</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.89</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.143</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Allele frequency</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">223 (79.6%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">152 (72.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">57 (20.4%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">58 (27.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> score</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.523</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.067</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">OR (95% CI)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.670 (0.440&#x02013;1.019)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>rs4930767</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Genotype frequency</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T/T</td><td align="left" rowspan="1" colspan="1">51 (36.2%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">43 (41.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">68 (48.2%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">44 (41.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">C/C</td><td align="left" rowspan="1" colspan="1">22 (15.6%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18 (17.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> score</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.976</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.614</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Allele frequency</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">170 (60.3%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">130 (61.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">112 (39.7%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">80 (38.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> score</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.133</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.779</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">OR (95% CI)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.071 (0.742&#x02013;1.545)</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="T2F1"><label>*</label><p>p &#x0003c; 0.05.</p></fn><fn id="T2F2"><label>1</label><p>For rs6489630, there were only 140 AD patients.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Characteristics of subjects aged &#x0003c;65 years (n = 163)</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">AD (n = 86)</th><th align="left" rowspan="1" colspan="1">NC (n = 77)</th><th align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> or F score</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">57.38 &#x000b1; 5.28</td><td align="left" rowspan="1" colspan="1">57.23 &#x000b1; 6.21</td><td align="left" rowspan="1" colspan="1">0.028</td><td align="left" rowspan="1" colspan="1">0.868</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex ratio (M/F)</td><td align="left" rowspan="1" colspan="1">43/43</td><td align="left" rowspan="1" colspan="1">36/41</td><td align="left" rowspan="1" colspan="1">0.171<xref ref-type="table-fn" rid="T3F1"><sup>*</sup></xref></td><td align="left" rowspan="1" colspan="1">0.754</td></tr></tbody></table><table-wrap-foot><fn><p>Values represent number of patients or means &#x000b1; SD.</p></fn><fn id="T3F1"><label>a</label><p>The &#x003c7;<sup>2</sup> score. One-way ANOVA with post hoc tests (Tukey) for age: AD versus NC.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Association between <italic>NTF-3</italic> and EAD patients aged &#x0003c;65 years</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">AD (n = 85)<xref ref-type="table-fn" rid="T4F1"><sup>1</sup></xref></th><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">NC (n = 77)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>rs6332</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Genotype frequency</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">G/G</td><td align="left" rowspan="1" colspan="1">21 (24.7%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">30 (39.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">46 (54.1%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">38 (49.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">A/A</td><td align="left" rowspan="1" colspan="1">18 (21.2%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">9 (11.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> score</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.967</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.083</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Allele frequency</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">88 (51.8%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">98 (63.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">82 (48.2%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">56 (36.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> score</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.687</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.033*</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">OR (95% CI)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.631 (1.045&#x02013;2.545)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>rs6489630</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Genotype frequency</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">C/C</td><td align="left" rowspan="1" colspan="1">56 (66.7%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">38 (49.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">25 (29.8%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">34 (44.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">T/T</td><td align="left" rowspan="1" colspan="1">3 (3.5%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">5 (6.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> score</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">5.025</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.081</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Allele frequency</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">137 (81.5%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">110 (71.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">31 (18.5%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">44 (28.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> score</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.605</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.035*</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">OR (95% CI)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.566 (0.335&#x02013;0.955)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>rs4930767</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Genotype frequency</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T/T</td><td align="left" rowspan="1" colspan="1">31 (36.5%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">32 (41.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">41 (48.2%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">33 (42.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">C/C</td><td align="left" rowspan="1" colspan="1">13 (15.3%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">12 (15.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> score</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.527</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.768</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Allele frequency</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">103 (60.6%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">97 (63%)</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">67 (39.4%)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">57 (37%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> score</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.197</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.731</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">OR (95% CI)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.107 (0.707&#x02013;1.734)</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>* p &#x0003c; 0.05.</p></fn><fn id="T4F1"><label>1</label><p>For rs6489630, the re were only 84 AD patients.</p></fn></table-wrap-foot></table-wrap></floats-group></article>